The purpose of this study is to collect adverse events and identify risk factors in patients that are taking Dolocordralan Extra 25® and Dolocordralan Extra Forte®
Study Type
OBSERVATIONAL
Enrollment
374
Local Institution
San Miguel, Lima region, Peru
Incidence rate of adverse events (AEs) in patients receiving treatment with Dolocordralan Extra 25 and and Dolocordralan Extra Forte in patients from Metropolitan Lima records
Ongoing events will be followed up until event resolution
Time frame: Approximately 13 months
Observed AEs in patients receiving treatment with Dolocordralan Extra 25 and Dolocordralan Extra Forte in patients from Metropolitan Lima records
Time frame: Approximately 13 months
Risk factors in patients experiencing adverse events while receiving treatment with Dolocordralan Extra 25 and Dolocordralan Extra Forte in patients from Metropolitan Lima records
Risk factors: medical history, concomitant diseases and concomitant treatment
Time frame: Approximately 13 months
Drug utilization factors in patients receiving treatment with Dolocordralan Extra 25 and Dolocordralan Extra Forte in patients from Metropolitan Lima records
Drug utilization factors: Dosing frequency, intake conditions, storage, and concomitant medications
Time frame: Approximately 13 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.